Michael Tolentino

Company: Aviceda Therapeutics

Job title: Co-Founder and Chief Innovation Officer and Board Member

Seminars:

Roundtable Discussion: Navigating the Current Anti-VEGF Treatment & Paving the Path for the Future of Retinal Vascular Disease Drug Development for Improved Patient Care 3:10 pm

Preclinical Models Table: Discovering the latest preclinical models – in vivo, in vitro and ex vivo – being developed and implemented to accurately reflect the retinal vascular environment such as a 3D model of the blood retinal barrier plus expressing key physiological and biological characteristics Beyond VEGF Table: Exploring novel target pathways, beyond VEGF, for…Read more

day: Conference Day 1

Targeting Underlying Retinal Inflammation to Avoid Disease Progression to Wet AMD 4:10 pm

Developing anti-inflammatory approaches by targeting complement pathway in combination with using anti-VEGF Tackling the challenges of complement inhibition molecules upregulating VEGF production and the subsequent progression of Wet AMD by combining salic acid mimetics Utilizing Siglecs with an off switch in addition to being activated to control the expression according to the level of inflammation…Read more

day: Conference Day 1